Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

TriApex Laboratories Files for Hong Kong IPO – Next-Generation CRO with 240+ NMPA Approvals

Fineline Cube Jun 16, 2026
Company Deals

Ningbo Sanxing Medical Electric Files HKEX Prospectus with Dual Business Model in Power Equipment and Rehabilitation Services

Fineline Cube Jun 15, 2026
Company Deals Hospital Medical Device

Baheal Pharma Partners with Jinan Junxin Hospital to Launch ZAP-X Precision Radiosurgery Center

Fineline Cube Jun 15, 2026
Company Deals

Lannacheng Biotechnology Files HKEX Prospectus with 13-Candidate Radiopharmaceutical Pipeline

Fineline Cube Jun 15, 2026
Company Deals

SSY Group Secures Exclusive China License for OPT101, Novel Peritoneal Dialysis Therapy from Opterion Health

Fineline Cube Jun 15, 2026
Policy / Regulatory

China’s NHSA Receives Record 818 Drug Applications for 2026 National Reimbursement Drug List Adjustment

Fineline Cube Jun 15, 2026
Company Drug

Shanghai Leadingtac Secures NMPA Approval for LT-010391 – China’s First Clinical-Stage Oral KRAS-G12D Degrader

Fineline Cube Jun 16, 2026
Company Drug

Fosun Pharma Secures NMPA Approval for Fumaining in Pediatric Langerhans Cell Histiocytosis – Expands MEK Inhibitor Franchise

Fineline Cube Jun 16, 2026
Company Drug

Enhertu Wins China NMPA Approval for Second‑Line HER2‑Positive Gastric Cancer

Fineline Cube Jan 22, 2026

AstraZeneca plc (AZ, NASDAQ: AZN) and Daiichi Sankyo Company, Limited (TYO: 4568) announced that Enhertu (trastuzumab deruxtecan)...

Company Drug

AstraZeneca’s Imfinzi Wins China Approval for Endometrial Cancer, Securing Seventh Indication

Fineline Cube Jan 22, 2026

AstraZeneca (AZ, NASDAQ: AZN) announced that Imfinzi (durvalumab) has been officially approved in China for use...

Company Medical Device

HeartCare Medical’s Intracranial Drug‑Eluting Stent Gets NMPA Filing Nod

Fineline Cube Jan 22, 2026

Shanghai HeartCare Medical Technology Co., Ltd (HKG: 6609) announced that China’s National Medical Products Administration...

Company Medical Device

Abbott’s TactiFlex Duo Wins CE Mark for Atrial Fibrillation Treatment in Europe

Fineline Cube Jan 22, 2026

Abbott (NYSE: ABT) announced it has received CE Mark approval in Europe for the TactiFlex Duo...

Company Drug

Lilly’s Sofetabart Wins FDA Breakthrough Status for Platinum‑Resistant Ovarian Cancer

Fineline Cube Jan 22, 2026

Eli Lilly and Company (NYSE: LLY) announced that the U.S. Food and Drug Administration (FDA) has...

Company R&D

Ascletis Selects ASC37 as Clinical Candidate for Monthly Triple Agonist Therapy

Fineline Cube Jan 22, 2026

Ascletis Pharma Inc. (HKG: 1672) announced it has selected ASC37, a next‑generation once‑monthly subcutaneous GLP‑1R/GIPR/GCGR triple‑agonist...

Company Deals

Novavax Licenses Matrix-M Adjuvant to Pfizer in $530M Deal

Fineline Cube Jan 22, 2026

Novavax, Inc. (NASDAQ: NVAX) entered into a license agreement with Pfizer Inc. for non‑exclusive rights to...

Company Drug

Henlius’s HLX701 Gets NMPA Nod for Phase Ib/II Advanced CRC Combination Study

Fineline Cube Jan 22, 2026

Shanghai Henlius Biotech, Inc. (HKG: 2696) announced that China’s National Medical Products Administration (NMPA) has...

Company Deals

BioRay Pharmaceutical Files HKEX IPO, Backed by First‑in‑Class Autoimmune and Oncology Pipeline

Fineline Cube Jan 22, 2026

Zhejiang-based BioRay Pharmaceutical Co., Ltd announced an initial public offering (IPO) filing to the Hong...

Company Deals

BMS Partners with Microsoft on AI‑Powered NSCLC Detection Platform

Fineline Cube Jan 22, 2026

Bristol‑Myers Squibb (BMS, NYSE: BMY) announced a collaboration with Microsoft to accelerate early detection of non‑small...

Company Deals

Bayer Partners with Vanderbilt in 5‑Year Deal to Accelerate Cardio‑Renal Drug Discovery

Fineline Cube Jan 22, 2026

Bayer AG (ETR: BAYN) and Vanderbilt University Medical Center (VUMC) announced a strategic five‑year collaboration to...

Company Deals

Hangzhou Diagens Biotechnology Files HKEX IPO for Medical Imaging AI Platform

Fineline Cube Jan 22, 2026

Hangzhou Diagens Biotechnology Co., Ltd. announced a filing for an initial public offering (IPO) to...

Others

Hengrui’s SHR-9839 + HRS-4642 Combo Cleared for Advanced CRC Trials

Fineline Cube Jan 22, 2026

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276, HKG: 1276) announced that China’s National Medical Products Administration (NMPA)...

Company Deals

GSK Acquires RAPT Therapeutics for $2.2 Billion, Adding Ozureprubart for Food Allergy Protection

Fineline Cube Jan 22, 2026

GlaxoSmithKline plc (GSK, NYSE: GSK) announced a definitive agreement to acquire RAPT Therapeutics (NASDAQ: RAPT) for USD 58.00...

Company Deals Drug

Alteogen Licenses ALT‑B4 Hyaluronidase to Tesaro for $285M Subcutaneous Dostarlimab Deal

Fineline Cube Jan 22, 2026

Alteogen Inc. (KOSDAQ: 196170) announced an exclusive license agreement with Tesaro, a GSK subsidiary, granting worldwide...

Company Drug

Shanghai Pharma’s iNKT Cell Therapy B023 Gets NMPA Nod for Advanced Solid Tumors

Fineline Cube Jan 22, 2026

Shanghai Pharmaceuticals Holding Co., Ltd (SPH, HKG: 2607, SHA: 601607) announced that its B023 cell...

Company Drug

Biokin’s Iza-bren ADC Receives NMPA Filing Acceptance for ESCC, World’s First EGFR×HER3 Bispecific

Fineline Cube Jan 22, 2026

Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506) announced that China’s National Medical Products Administration (NMPA)...

Company Drug

Kawin Technology Withdraws Hepatitis B Filing for Peginterferon Alfacon‑2 After NMPA Feedback

Fineline Cube Jan 22, 2026

Kawin Technology (SHA: 688687) announced it has voluntarily withdrawn its market filing for peginterferon alfacon‑2...

Company Deals

Eyebright Medical to Acquire Control of Delta Medical in $143 M Sports‑Medicine Deal

Fineline Cube Jan 22, 2026

Eyebright Medical Technology Co., Ltd (SHA: 688050) announced plans to acquire a controlling stake of...

Company

AstraZeneca to Delist from Nasdaq, Shift Direct NYSE Listing in Share Structure Unification

Fineline Cube Jan 22, 2026

AstraZeneca plc (AZ, NASDAQ: AZN) announced it will delist its American Depositary Shares (ADS) and debt...

Posts pagination

1 … 71 72 73 … 683

Recent updates

  • Shanghai Leadingtac Secures NMPA Approval for LT-010391 – China’s First Clinical-Stage Oral KRAS-G12D Degrader
  • Fosun Pharma Secures NMPA Approval for Fumaining in Pediatric Langerhans Cell Histiocytosis – Expands MEK Inhibitor Franchise
  • TriApex Laboratories Files for Hong Kong IPO – Next-Generation CRO with 240+ NMPA Approvals
  • Ningbo Sanxing Medical Electric Files HKEX Prospectus with Dual Business Model in Power Equipment and Rehabilitation Services
  • Gritpharma Secures NMPA Approval for Doxylamine as China’s First Novel Short-Term Insomnia Treatment
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Shanghai Leadingtac Secures NMPA Approval for LT-010391 – China’s First Clinical-Stage Oral KRAS-G12D Degrader

Company Drug

Fosun Pharma Secures NMPA Approval for Fumaining in Pediatric Langerhans Cell Histiocytosis – Expands MEK Inhibitor Franchise

Company Deals

TriApex Laboratories Files for Hong Kong IPO – Next-Generation CRO with 240+ NMPA Approvals

Company Deals

Ningbo Sanxing Medical Electric Files HKEX Prospectus with Dual Business Model in Power Equipment and Rehabilitation Services

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.